Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Dermalogen was an injectable dermal filler composed of a homologous collagen dispersion derived from acellular, aseptically processed cadaveric human tissue. Developed by Collagenesis, it was primarily indicated for facial soft-tissue augmentation, including the treatment of wrinkles and soft tissue defects. As a human-derived product, it offered an advantage over bovine collagen fillers (such as Zyplast) by eliminating the need for allergy pretesting and being suitable for patients sensitized to bovine proteins. Although it demonstrated clinical persistence and histological behavior similar to bovine collagen, it was classified as a transplantable tissue/device rather than a standard pharmaceutical drug. The product is currently discontinued and no longer available on the market.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Dermalogen.